Sonar to Improve the Quality of AI-Generated Code, Provide Automated Fix Recommendations
3.10.2024 16:00:00 EEST | Business Wire | Press release
Sonar, the leading Clean Code solution provider, today announced two new product capabilities for today’s AI-driven software development ecosystem. These new capabilities are designed to support better software development in two critical and distinct ways – Sonar AI Code Assurance and Sonar AI CodeFix improve the quality of code produced by generative AI and enhance Sonar’s offering with AI to deliver a better developer experience, respectively. Both capabilities deepen Sonar’s commitment to the delivery of high-quality, secure code and increasing developer productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003439224/en/
Sonar introduces AI Code Assurance and AI CodeFix to improve the quality of code produced by generative AI. (Photo: Business Wire)
AI Code Assurance helps organizations ensure the quality of AI-generated code by thoroughly analyzing the codebase for issues, ensuring that projects using AI tools to generate code meet high standards of quality and security. Today, bad code is already estimated to cost businesses more than a trillion dollars, making it critical for AI-generated code, which promises to increase the volume of code written, to be comprehensively checked for quality and security issues.
“AI is transforming the way developers work, streamlining processes, and reducing the toil associated with writing code. As the adoption of AI coding assistants grows, however, we are seeing a new issue emerge: code accountability. AI-generated code needs review by developers, but accountability for doing this is increasingly diluted. As a result, we’re seeing the review step frequently being shortchanged,” said Tariq Shaukat, CEO of Sonar. “With AI Code Assurance, we’re helping organizations ensure that AI written code receives the high level of quality and security review that you would expect from your developers.”
AI CodeFix allows developers to seamlessly resolve issues detected by Sonar's code analysis engine with a single click, directly within their workflow. The AI-powered fix recommendations help streamline developer workflows, speed up issue remediation, and improve the developer experience. As leading research has established, developer experience improves with the automation that AI provides. For example, McKinsey reported that developers using generative AI tools in their work stream are “twice as likely to report overall happiness, fulfillment, and a state of flow” than those who aren’t.
“AI CodeFix helps developers streamline their workflow and ramp up their productivity. Rather than switching between solutions or manual efforts, we’re putting remediation options for Sonar-identified issues right in front of the people working on them – and giving them the ability to fix the issues in an instant. We’re excited to see how our users adopt this capability and better understand how we can further integrate AI into our solutions to improve the developer experience,” said Fabrice Bellingard, VP of Product at Sonar.
The features are currently available for both SonarQube and SonarCloud.
AI Code Assurance for Confidence in Code Quality
With AI Code Assurance for SonarQube and SonarCloud, developers can be confident that their AI-generated code is clean and secure. By implementing the Sonar AI Code Assurance workflow, organizations have the assurance that all code (AI-generated and human-developed) has been thoroughly scanned for issues and that projects leveraging AI tools are meeting high standards of quality and security.
AI Code Assurance capabilities include:
- Project Tagging: Developers can easily tag projects that contain AI-generated code, initiating a comprehensive analysis through the Sonar AI Code Assurance workflow.
- Quality Gate Enforcement: An optimized quality gate for AI-generated code ensures that only code meeting strict quality and security standards is approved for production.
- AI Code Assurance Approved Badge: Projects that pass the quality gate receive a badge signifying that the code has gone through a rigorous AI-ready analysis.
AI CodeFix for Fast Issue Remediation
Fast-paced software development environments require solutions that enhance productivity, reduce time-to-market, and maintain high code quality. Today, millions of Sonar users can detect and fix issues in their code leveraging Sonar’s database of code rules and best practices. Now, at the click of a button, developers can use AI CodeFix to automatically generate solutions to issues in the same SonarQube and SonarCloud user interface where they review issues.
AI CodeFix capabilities include:
- Instant Code Fixes: Minimize manual debugging efforts and increase productivity by automatically generating code fix suggestions.
- Contextual Understanding of Sonar findings: Leverages LLMs to understand code context and provide relevant fixes.
- Seamless Integration: Developers fix issues directly within their IDE using SonarLint connected mode, ensuring a smooth workflow.
- Continuous Learning: Ongoing suggestion improvements based on user feedback
- Multi-Language Support: Supports flagship programming languages such as Java, JS/TS, C#, Python, and C/C++.
AI Code Assurance is now available on SonarQube and will be generally available in SonarCloud by the end of October. AI CodeFix is available for early access in SonarQube Enterprise Edition, SonarQube Data Center Edition, and SonarCloud Team and Enterprise plans.
For more information on the new features, visit our AI features page at https://www.sonarsource.com/solutions/ai/.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003439224/en/
Contacts
Media
Katie Hyman
Senior PR Manager for Sonar
(707) 291-1469
press@sonarsource.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom